Apolipoprotein E (ApoE) Assay
Reagent | Apolipoprotein E (ApoE)
A Genetic Risk Factor for CVD & Alzheimer’s Disease
Benefits of the Randox ApoE Assay
A correlation coefficient of r=1.00 was displayed when the Randox apoE assay was compared to commercially available methods.
The Randox apoE assay displayed a precision of <2.79% CV.
Extensive measuring range
The Randox apoE assay has a measuring range of 1.04 – 12.3mg/dl for the comfortable detection of clinically important results.
The apoE assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Dedicated calibrator and controls available
Randox offer dedicated apolipoprotein calibrator and controls for a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox apoE assay on a variety of clinical chemistry analysers.
The apolipoproteinE (APOE) gene provides instructions for the production of the apolipoprotein E (apoE) protein. The apoE protein binds with lipid forming lipoproteins which are responsible for the transportation of cholesterol and other lipids through the bloodstream 1.
Apolipoprotein E (apoE) is a multifunctional glycoprotein with central roles in lipid metabolism, neurobiology, and neurodegenerative diseases. ApoE has three major isoforms (apoE2, apoE3, and apoE4) all of which have different effects on lipid and neuronal homeostasis (fig 1). The key function of apoE is to mediate the binding of lipoproteins or lipid complexes in the plasma or interstitial fluids to specific cell-surface receptors. These receptors internalise apoE-containing lipoprotein particles and so apoE participates in the distribution or redistribution of lipids among various tissues and bodily cells 2. The e3 allele is the most of the three and may be considered an ancestral allele. The e4 allele is more common in those of Northern European ancestry and lower in those of Asian ancestry 3.
Fig. 1. ApoE isoforms and their properties 2
Both apoE2 and apoE4 alleles are associated with cardiovascular disease (CVD).
As apoE2 binds defectively to LDL receptors, apoE2 homozygosity can precipitate type III hyperlipoproteinemia, however, only occurs when another condition, including: diabetes, oestrogen deficiency, hypothyroidism, or obesity, leads to the overproduction of VLDL or fewer LDL receptors, overwhelming the limited ability of apoE2 to mediate the clearance of triglyceride-rich and cholesterol-rich β-VLDL. Other dominant and recessive mutations in apoE that affect residues in or around the receptor binding region also causes type III hyperlipoproteinemia 3.
ApoE3 increases LDL levels in plasma and the risk of atherosclerosis. The lipoprotein-binding preference of apoE4 to large (30-80nm), triglyceride-rick VLDL, is associated with elevated levels of LDL. The enrichment of VLDL with apoE4 accelerates their clearance from the plasma by receptor-mediated endocytosis in the liver and consequently, LDL receptors are downregulated, and LDL levels rise 3.
ApoE4 is the major genetic risk factor, or causative gene, for Alzheimer’s disease (AD) and other neurological disorders, including poor clinical outcomes following traumatic brain injury, stroke, frontotemporal dementia, Down syndrome, certain patients with Parkinson’s disease, and Lewy body disease 3.
Apo E4 drastically affects AD with 65-80% of all AD patients carrying at least one apoE4 allele. ApoE4 increases the risk of developing AS 4-fold (one allele) and 14-fold (two allele). Carrying one e4 allele is not uncommon with approximately 25% of people worldwide having at least one E4 allele. Fig. 2 illustrates the apoE-mediated pathogenic pathways leading to AD, with amyloid β playing a key role 3.
Fig. 2. ApoE-mediated pathogenic pathways leading to Alzheimer’s Disease 4
 Huang Y, Mahley RW. Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer’s diseases. Neurobiology of Disease 2014; 72(Part A): 3-12.
 Genetics Home Reference. APOE gene: apolipoprotein E. https://medlineplus.gov/genetics/gene/apoe/ (accessed 9 October 2020).
 Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of Molecular Medicine (Berlin, Germany) 2016; 94: 739-746.
 Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer’s disease. Current Opinion in Lipidology 2017; 28(1): 60-67.
Reagent | Immunoglobulin (IgE)
A Marker of Allergic Diseases
Benefits of the Randox Apo C-II Assay
A correlation coefficient of r=1.00 was displayed when the Randox methodology was compared against commercially available methods.
The Randox IgE assay displayed a precision < 4.0% CV.
Excellent measuring range
The Randox IgE assay has a measuring range of 19.6 – 1007IU/ml for the comfortable detection of clinically important results.
The Randox IgE assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Calibrator and controls available
Dedicated IgE calibrator and specific protein controls available for a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox IgE assay on a variety of clinical chemistry analysers.
Immunoglobulin E (IgE) is one of five classes of immunoglobulins (IgA, IgD, IgE, IgG and IgM). IgE was the last immunoglobulin to be discovered. However, since it’s discovery, vast amounts of research have been aimed at characterising its physiological and clinical significance’s. Whilst IgEs chemical structure is unique compared to the rest of the immunoglobulin family (lacks a ‘hinge’ region in the centre of the molecule and gets replaced by the C-epsilon2 domain), it has an array of physiological functions. For immunoglobulin E to fulfil its function, the Fc portion of the antibody must bind to a given cellular receptor located on certain cell types, such as eosinophil or mast cells. Whilst many an array of cellular receptors have been identified, the main ones are Fc-epsilon-RI, Fc-epsilon-II and CD23. Fc-epsilon-RI is the high affinity receptor located on basophils, dendritic cells, eosinophils, mast cells and macrophages and is responsible for immediate hypersensitivity reactions, enhanced cytokine production, parasitic immunity, and antigen presentation 1.
It is believed that immunoglobulin E evolved as a defence mechanism against parasitic infestation. The major sites of parasitic invasion are the gut, respiratory tract and skin, the typical allergic response sites. IgE antibodies play a key role in the early recognition of foreign material or a general potentiation of the immune system response through improved antigen presentation. An allergy triggered by IgE could be beneficial to the host as the typical allergic reactions include: sneezing, coughing, inflammation, bronchoconstriction and vomiting, to expel allergenic proteins from the body. Different allergens stimulate the production of corresponding allergen-specific immunoglobulin E antibodies 2. The antigen-dependent activation of tissue mast cells that have specific immunoglobulin E bound to their surface is the central event in acute allergic reactions. IgE specific allergens include: allergic or atopic asthma, atopic dermatitis (eczema), food allergies such as peanut and shellfish, allergic rhinitis (hay fever), house dust mite, latex allergy, dog or cat allergies 2, 3.
Specific Proteins Controls
Reagents Resource Hub
Reagent | Apolipoprotein C-II (Apo C-II)
In Association with Hypertriglyceridemia
Benefits of the Randox Apo C-II Assay
The immunoturbidimetric method limits interference from Bilirubin, Haemoglobin, Intralipid® and Triglycerides, producing more accurate results.
A correlation coefficient of r=1.00 was displayed when the Randox apo C-II assay was compared to commercially available methods.
Excellent measuring range
The Randox apo C-II assay has a measuring range of 1.48 – 9.70mg/dl for the comfortable detection of clinically important results.
The Randox apo C-II assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Dedicated calibrator and controls available
Randox offer dedicated apolipoprotein calibrator and controls for a complete testing package.
Applications available detailing instrument-specific settings for the convenient use of the Randox apo C-II assay on a variety of clinical chemistry analysers.
Apo C – II is a 79-amino acid protein synthesised in the liver and is the co-factor for lipid transport in the bloodstream 1. Apo C – II is a surface constituent of lipoproteins and the C – terminal helix activates lipoprotein lipase (LPL) 2. The active peptide of apo C – II corresponds to residues 44 – 79 and has been identified to reverse the symptoms of genetic apo C – II deficiency. Moreover, LPL is also a key enzyme in the regulation of triglyceride levels 3.
Both an excess and deficiency of apo C – II is associated with hypertriglyceridemia and reduced LPL activity. Elevated levels of apo C-II is associated with excess triglyceride – rich particles and altercations in the distribution of HDL particles, increasing the risk of CVD 4. Whilst extremely rare, a deficiency in apo C-II results in excess fasting hypertriglyceridemia and chylomicronemia. Hypertriglyceridemia can cause eruptive xanthomas, pancreatitis, hepatosplenomegaly and lipemia retinalis. Biologically and clinically, apo C – II deficiency closely mimics LPL deficiency. Synonyms for apo C-II deficiency include: C – II an apolipoproteinemia and hyperlipoproteinemia type Ib 5.
 Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, et al. Global Structure and Dynamics of Human Apolipoprotein CII in Complex with Micelles: Evidence for Increased Mobility of the Helix Involved in the Activation of Lipoprotein Lipase. Biochemistry 2003; 42(7): 1872-1889.
 Storjohann R, Rozek A, Sparrow JT, Cushley RJ. Structure of a biologically active fragment of human serum apolipoprotein C-II in the presence of sodium dodecyl sulfate and dodecylphosphocholine. Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids 2000; 1486(2-3): 253-264.
 Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism: Clinical and Experimental 2012; 61(7): 906-921.
 Meyers NL, Larsson M, Olivecrona G, Small DM. A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II*. Journal of Biological Chemistry 2015; 290(29): 18029-18044.
 Hoffmann MM, März W. Apo C-II Deficiency. Encyclopedia of Molecular Mechanisms of Disease 2009; 132(133): https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_137 (accessed 6 November 2019).
The World Heart Federation (WHF) is the acting global voice in leading the universal fight against cardiovascular disease (CVD). Part of the WHF mission is to ensure heart health equity for everyone. They believe everybody is entitled to cardiovascular health and well-being through health promotion, access to prevention, control and management of CVD 1.
World Heart Day falls on the 29th September where people make a promise to promote and implement healthier lifestyles to maintain a happy and healthy heart, reducing the potential risks of heart disease and stroke. CVD takes the lead being the number one cause of death world-wide 2 relating to all heart and circulatory diseases consisting of coronary heart disease, angina, heart attack, congenital heart disease, hypertension, stroke and vascular dementia 3.
According to the World Health Organisation2:
- An estimated 17.9 million people died from CVD in 2016, representing 31% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.
- Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by CVD.
- Most cardiovascular diseases can be prevented by addressing behavioural risk factors such as tobacco use, unhealthy diet and alcohol abuse.
Cytokines have a central role within the immune system; they are a category of signalling molecules that mediate and regulate immunity, inflammation and hematopoiesis 4. Cytokine and inflammatory mechanisms have major implications for the vascular system and can lead to CVD.
Cytokines exist in broad families that are structurally related but exhibit diverse function. The major classes of cytokines include: pro- and anti-inflammatory cytokines, cytokines of neutrophil and eosinophil recruitment and activation, cytokines derived from T-helper (Th) and T-regulatory (Tregs) cells, and cytokines of T-cell recruitment and growth factors. 5
Randox offers a comprehensive menu of 26 cytokine, cytokine receptors and growth factors over four multi-analyte arrays. Each cytokine assay is performed on biochip array technology with spatially discrete test regions containing antibodies specific to each of the analytes. The combination of highly specific antibodies and advanced chemistries enables up to 12 cytokines and growth factors to be detected simultaneously in a single sample.
Cytokine Array I Cytokine Array III
- Epidermal Growth Factor (EGF) – Granulocyte Macrophage Colony Stimulating
- Interferon-y – Interleukin-5
- Interleukin-1a – Interleukin-15
- Interleukin-1b – Macrophage Inflammatory Protein-1a
- Monocyte Chemotactic Protein-1
- Tumour Necrosis Factor-a
- Vascular Endothelial Growth Factor
Cytokine Array IV Cytokine Array V
- Matrix Metalloproteinase-9 – Interleukin-3
- Soluble IL-2 Receptor a – Interleukin-7
- Soluble IL-6 Receptor – Interleukin-13
- Soluble Tumour Necrosis Factor Receptor I – Interleukin-12 p70
- Soluble Tumour Necrosis Factor Receptor II – Interleukin-23
Key Benefits of Randox Cytokine Arrays:
- Multiplex testing from a single sample.
- Suitable for human serum and plasma samples.
- Small sample volume required.
- Excellent analytical performance.
- Fast throughput.
- Applicable to fully automated and semi-automated Evidence analysers.
Randox manufacture the majority of assay raw materials in-house and can therefore take a more tailored approach, by adapting assays to the needs of your research project to best fit your individual requirements.
Randox Biosciences Products and Services
Want to know more about Randox?
Contact us or visit our homepage to view more.
Global healthcare company Randox Laboratories has today announced Liverpool-based charity the Tim Cogley Cardiac Screening Foundation, located near its Liverpool Randox Health clinic, and Townland Boxing Club, near its Crumlin headquarters in Northern Ireland, as its official charity partners for 2019/2020.
Randox staff in the UK and Ireland will be fundraising for these causes through a range of events and initiatives throughout the year, including individual staff fundraising activities and the company’s popular Christmas Raffle for staff in December.
Randox Founder and Managing Director, Dr. Peter FitzGerald, commented;
“We are delighted to partner with the Tim Cogley Cardiac Screening Foundation in Liverpool and Townland Boxing Club in Glenavy. Both are very worthy causes close to the hearts of those living near two of our health check clinics – Randox Health Liverpool in Exchange Station and Randox Health Crumlin in Northern Ireland.
“Our partnerships with each of these charities focus on the health and wellbeing, in particular, of young people. You are never too young to start caring about your health and thinking of your future wellbeing.
“Indeed, our research and development teams have found that signs of ill-health often appear in the body at an early age but symptoms may not appear until later in life. It is paramount that the health of young people is prioritised at the earliest stage and when preventable illnesses and conditions can be stopped in their tracks or more effectively managed.”
Frank Cogley, father of Tim and founder of the Tim Cogley Cardiac Screening Foundation, commented;
“The Tim Cogley Cardiac Screening Foundation is dedicated to providing free cardiac screenings and education for young adults in Merseyside and the Wirral. The essence of the charity, and its whole approach of reaching out to help others, reflects Tim’s character and, in that sense, keeps alive his driving force. I can’t imagine a legacy more in tune with the generous, kind and supportive person that was Tim.”
Tim Cogley, an apparently fit and healthy 34-year-old from Heswall, England, suffered a fatal heart attack in April 2017. Despite showing no symptoms, Tim had a 75% cholesterol blockage of the left descending coronary artery. The Tim Cogley Cardiac Screening Foundation was set up by family and friends in Tim’s memory to offer free heart screening to those aged 18 to 40 within the Merseyside area, an age range where little heart screening currently is offered.
“We have enjoyed a close working relationship with Randox Health Liverpool since our inception in 2017 and are thrilled to have been chosen as one of the company’s staff charity partners.
“The money raised by Randox staff will help provide cardiac screenings and facilitate a range of educational programmes which, by sharing Tim’s story, will illustrate the need to be aware of key health indicators from a young age.
“Making young people aware of their vital signs, such as blood pressure, will go a long way in preventing future young deaths from preventable heart conditions, and we look forward to delivering this message with the help of staff from Randox Health.”
In addition to cardiac screening programmes, the Tim Cogley Cardiac Screening Foundation is committed to delivering positive, action-focused and life-changing educational sessions which focus on delivering information lifestyle changes which can have positive benefits for young people.
Randox Founder and Managing Director, Dr. Peter FitzGerald, said;
“The Tim Cogley Cardiac Screening Foundation has already made a difference to young people in the Liverpool area both with the detection of early cardiac issues through its free screening programme and in its education endeavours. The story of Tim Cogley is a tragic one of a life ended too soon. The courage and commitment of his family to create a positive legacy in his name is to be admired and we look forward to joining with them through this Randox staff charity partnership.”
Randox’s second charity partner, Townland Boxing Club in Glenavy, was founded in 2008 by a group of dedicated people interested in the sport of boxing and improving youth facilities in the area.
The amateur boxing club, which is a completely voluntary organisation, was opened with a purpose to give young people in the area a place to meet, form friendships and learn the discipline, respect and skill required to become an amateur boxer.
Thomas Quinn, head coach at Townland Boxing Club, said;
“Randox is a key employer in the area with tremendous influence and we look forward to partnering with them as we continue to bring boxing facilities and training to young people in the wider Glenavy area. From the admin staff to coaches, everyone here works on a voluntary basis and we rely on the generosity of others, such as Randox, to keep our services continuing for generations to come.”
Randox Founder and Managing Director, Dr. Peter FitzGerald, said;
“Randox’s global headquarters has been based in Crumlin since the company was founded in 1982. We are proud to hold longstanding relationships with the local community here and our new staff charity partnership with Townland Boxing Club in Glenavy signals our continued commitment to the wellbeing of Crumlin and the surrounding area.”
Please contact Randox PR using the contact details below to arrange an interview, or for more information.
Phone: 028 9442 2413.
Or email: email@example.com
What is Familial Hypercholesterolemia?
Familial Hypercholesterolemia (FH) is a genetic condition which is passed down from the parents’ genes. The British Heart Foundation has highlighted that FH is caused by a genetic mutation which means the liver is unable to remove excess ‘bad’ cholesterol (LDL), therefore, the LDL level in the blood remains high.2 Someone who suffers with FH would have high cholesterol from birth which can cause other health issues including heart and circulatory disease.
Heart UK states that more than 260,000 people in the UK may have FH. However, less than 10% of this number have been diagnosed and therefore, may not be aware of their condition.3 However, to date there are no clear symptoms if someone has FH until it is considered too late.
Familial Hypercholesterolemia (FH) symptoms
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Grey-white cholesterol deposits around the corneas
If untreated, about 50% of men and 30% of women with FH will develop coronary heart disease by the time they are 55. More worryingly, on average in the UK, one person a day with FH has a heart attack. About a third of people don’t survive their first heart attack, and many who do survive will have damaged hearts.
The good news is that a 2008 study part-funded by the BHF found that people with FH who are diagnosed and treated before they develop heart disease generally live as long as people who don’t have FH. That’s why it is vitally important to get diagnosed as early as possible.
How Randox Biosciences can help
Randox Biosciences offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time. This allows results to be reported within days compared with NHS waiting lists which can be substantially longer.
Our two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes.
The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing. Genetic analysis for FH mutations also allows for more accurate diagnosis compared to lipid profiling.
Familial Hypercholesterolemia (FH) Arrays I & II:
LDLR – 38 mutations
APOB – 1 mutation
PCSK9 – 1 mutation
To find out more about the products that we offer, email us firstname.lastname@example.org
An event on preventative healthcare and cardiac screening is being delivered in Liverpool this week by a wealth of world-leading industry and academic speakers.
Hosted by the sponsor of the Randox Health Grand National, in association with Liverpool John Moores University, Liverpool Hope University and the Tim Cogley Cardiac Screening Foundation, the event, entitled the Preventative Cardiac and Metabolic Health Seminar, runs on Wednesday 3rd April and is open to the public.
It follows a morning of engaging fitness programmes, including boxing, taekwondo and indoor cycling, for local pupils and teachers from across Merseyside and Cheshire. During these exercises, which will also include the opportunity to experience life as a jockey by having a go on a horse simulator, the children will also have some physiological measurements taken, including their heart rate.
“Prevention is always better than cure”, says Managing Director Dr Peter FitzGerald. “Our aim is to empower people to take control of their health, to live longer and more healthy lives.
“We are delighted to be teaming up with Liverpool John Moores, Liverpool Hope and the Tim Cogley Cardiac Screening Foundation ahead of the Randox Health Grand National. The world’s greatest race offers us the perfect platform to spread our message of preventative health, and we look forward to sharing our knowledge with the audiences at this exciting event.”
This is the third year that the educational event from Randox Health has been held in the city, and for the second time will be championed by Frank Cogley of the Tim Cardiac Screening Foundation, whose son suffered a fatal heart attack due to a genetic condition. Frank is now working to raise the profile of cardiac health checks for young people.
“It’s been recently reported that at least 12 under-35s die from undiagnosed heart conditions every week in the UK. The current lack of routine screening of 18 to 40-year-olds leaves a gaping chasm in our healthcare provision.
“With our highly motivated partners, through events like this, we hope to redress this through lifestyle changes and preventative medical programmes.
“The Tim Cogley Cardiac Screening Foundation is committed to delivery positive, action-focused and life-changing programmes. I can’t imagine a legacy more in tune with the generous, kind and supportive person that was Tim.”
Tickets for the Randox Health seminar, which focuses on health screening and how the right approach can deliver significant benefits, are priced at £3 and are available at https://www.eventbrite.co.uk/e/preventative-cardiac-and-metabolic-health-seminar-tickets-59041545853?aff=ebdshpsearchautocomplete
£2.27 of each ticket payment will go towards the ‘Tim Cogley Cardiac Screening Foundation’ charity. Each attendee at the event will also be entered into a raffle on the day, with the winning prize being general admission tickets for the Randox Health Grand National on Saturday 6th April.
For further information please contact the Randox PR team by emailing email@example.com or phoning 028 9442 2413
National Heart Month is held every February to raise awareness and remind the public of the importance of taking care of your heart. Every day, your heart will beat approximately 100,000 times and it is responsible for pumping blood throughout the body via the circulatory system, supplying oxygen and nutrients to the tissues and removing carbon dioxide and other wastes. 1
British Health Foundation (BFH) states that over 7 million people are living with heart and circulatory disease in the UK: 3.5 million men and 3.5 million women. 2
There are many different heart conditions and problems that can arise which include angina, heart attack, heart failure and abnormal heart rhythms, congenital heart disease and inherited heart conditions which are highlighted further below:
Angina is a chest pain which is often caused when the coronary arties become partially blocked. It causes an uncomfortable feeling of heaviness or tightness which is often mistaken to indigestion. 3
Whereas a heart attack is when the arteries are completely blocked which can cause permanent damage to the heart muscle therefore, it is essential to be aware of the symptoms. The signs are similar to angina although it is more severe. This may include feeling pain in the arms, jaw, neck and back, lightheadness, sweating, nausea and breathlessness. 3
Heart failure is the most dangerous condition. It often occurs when the individuals heart is too weak to pump blood around the body making it difficult for the person to breathe. There are two types of heart failure. Acute heart failure which can occur suddenly or chronic heart failure which develops over time. 3
Being aware of the different types of heart disease and the symptoms can save a person’s life in the long-run. There are many ways to avoid developing heart disease. One of the simple changes could include having a healthier diet to reduce your risk of developing heart disease and maintaining a healthy weight. A healthy diet could include plenty of fruit and vegetables, starchy food, choosing whole grain varieties, including some dairy products and a small amount of fat and sugar in your diet. Exercising regularly can benefit your heart and its health, making small changes to your lifestyle can make a difference for example, walking to work or school instead of driving or taking public transport, taking the stairs instead of using the lift or even taking on a hobby! Quitting smoking, decreasing your alcohol intake, eating healthier and exercising more will make a huge impact to your health!
Randox offer the Cardiac Risk Prediction Array on their Evidence Investigator. We developed a rapid array which will allow all 19 SNPs to be genotyped simultaneously on one single sample. The genotype information is then put into an algorithm which weights each SNP and calculates a CHD genetic risk score. This score is combined with common risk factors and an overall CHD risk score is calculated. A SNP which can predict response to statin therapies is also included. The results are easy to interpret using our Evidence Investigator which allows for more accurate classification and prevention actions to be taken.
For further information about the Randox Cardiac Risk Prediction Array or our Evidence Investigator, please email: firstname.lastname@example.org or visit our newly improved website: https://goo.gl/8qkYkg
This February, Randox Health are focusing on Heart Health. Heart health is becoming a much greater talked about subject because of health trends and figures. There are around 7 million people living with heart and circulatory disease in the UK. Heart and circulatory disease causes more than a quarter (26%) of all deaths in the UK; that’s nearly 160,000 deaths each year – an average of 435 people each day or one death every three minutes. Facts like these from BHF show us how how important our hearts are! Maintaining and having a healthy heart is essential to cut down your risk of heart disease.
Ways to Improve your Health
There are a number of things you can do to lower your risk of getting heart disease, and at the same time improve overall health. Lets look at three ways to lower your risk and help you become healthier:
- Managing a healthy weight
- Eating healthier
- Getting active
What You Can Do
All three of the above will lower your risk of heart disease and all are linked so by improving one it will help the others. To manage a healthy weight, first you need to work out what a healthy weight is for you. There are two main ways to tell whether you need to lose weight: your Body Mass Index (BMI), and your waist measurement. the risk of heart disease begins to increase at a BMI of 23, and people with a BMI of 27.5 will be at high risk.
Men with a waist of over 94 cm are at an increased risk of heart diseases and over 102 cm are at a severe risk. Women with a waist over 80 cm are at an increased risk and at 88 cm are at a severe risk. If you fall in these risk areas, eating well and being more physically active can help you reduce your weight.
A healthy diet can help reduce your risk of developing coronary heart disease and stop you gaining weight. This also reduces your risk of diabetes and high blood pressure. A well-balanced diet should include at least 5 portions of fruit and veg a day. Try to vary the types of fruit and veg you eat.
You should try to replace saturated fats with small amounts of mono and polyunsaturated fats. Try and cut down on foods that contain trans fats as it can raise your cholesterol levels. Lowering your salt intake can improve your blood pressure and lower your chance of coronary heart disease. Eating a healthy well-balanced diet can make it a lot easier to control and maintain your weight.
Get Active! The BHF say that physical activity can help reduce your risk of heart and circulatory disease. It also links in and helps you control your weight! Being active reduces blood pressure and cholesterol and can even improve your mental health. If you do all three of these points not only will it lower your risks of heart disease but will improve your overall health!
Randox Health: What We Do and How We Can Help
This month we are focusing on heart heart, so make sure to check out our blogs with information about how to keep a healthy heart. If you’re worried about your heart health or have a family history of heart disease, contact a member of our team today for more information on how we could help you! We are determined to help you get to the heart of the matter and see what’s really going on with your heart. This Valentines day give a gift to the one you love that really matters, the gift of health.
Find out more here: https://www.randoxhealth.com/our-packages/